Hyperphagia: Clinical Trials

27 trials for Hyperphagia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

27 completed. 27 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 327Completed 27
Phase 23Completed 3

Follow Hyperphagia: new trials by email Literature Review of Hyperphagia trials Research Report on Hyperphagia

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition
NTCB01-1, NTCB-P - Parenteral Nutrition
Phase 3CompletedYuhan Corporation602024-11-142025-05-15
Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301
IN-C006 Peri inj., RPN301 - Parenteral Nutrition
Phase 3CompletedHK inno.N Corporation592022-08-092023-09-28
Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301
IN-C006 inj., RCN301 - Parenteral Nutrition
Phase 3CompletedHK inno.N Corporation602022-05-042023-09-28
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Setmelanotide, Placebo - Obesity, Genetic Obesity
Phase 3CompletedRhythm Pharmaceuticals, Inc.2962022-04-262026-11-12
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg - Bardet-Biedl Syndrome, POMC Deficiency
Phase 3CompletedRhythm Pharmaceuticals, Inc.192021-12-212024-11-26
Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral Nutrition
SmofKabiven emulsion for infusion, Hospital compounded "All in one" emulsion - Parenteral Nutrition, Surgery
Phase 3CompletedFresenius Kabi2732019-01-032021-08-02
Omegaven as Alternative Parenteral Fat Nutrition
Omegaven - Cholestasis, Cholestasis of Parenteral Nutrition
Phase 3CompletedUniversity of South Florida22018-10-232020-07-22
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
Teduglutide 0.05mg/kg, Teduglutide 0.025 mg/kg, Standard of Care - Short Bowel Syndrome
Phase 3CompletedShire592016-06-232021-06-09
Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition
multicomponent lipid emulsion, pure soybean oil lipid emulsion - Cholestasis
Phase 3CompletedThammasat University442013-12-012017-06-23
A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021
Teduglutide - Short Bowel Syndrome
Phase 3CompletedShire142012-05-212021-06-10
Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation
Oliclinomel N4, Compounded ternary parenteral nutrition admixtures - Nutrition Support
Phase 3CompletedBaxter Healthcare Corporation4582011-12-012013-02-01
Efficacy and Safety of a Fish Oil Containing Lipid Emulsion
fish oil containing lipid emulsion, MCT/LCT containing lipid emulsion - Parenteral Nutrition
Phase 3CompletedB. Braun Melsungen AG2402010-04-012012-01-10
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
teduglutide - Short Bowel Syndrome
Phase 3CompletedShire882009-09-212021-06-11
Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
teduglutide, placebo - Short Bowel Syndrome
Phase 3CompletedShire862008-11-252021-06-03
Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN
ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion - Parenteral Nutrition
Phase 2 / Phase 3CompletedEmory University1002008-11-012018-10-17
Safety During Use of Paediatric Triple Chamber Bag Formulas
Ped3CB - Infant Nutrition Disorders, Infant, Premature, Diseases
Phase 3CompletedBaxter Healthcare Corporation1612008-02-012011-02-25
Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition
SMOF lipid and Intralipid - Parenteral Nutrition
Phase 3CompletedFresenius Kabi752007-10-012010-08-27
The AOT (Acridine Orange and Taurolidine) Trial
taurolidine - Parenteral Nutrition, Infection
Phase 3CompletedRadboud University Medical Center602006-06-012009-02-11
Craving, Binge Eating and Obesity
bupropion, Placebo - Binge Eating Disorder, Obesity
Phase 2 / Phase 3CompletedYale University612005-12-012020-04-03
Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery
a combination of MCT, LCT , and Fish Oil - Inflammation, Cardiac Surgical Procedures
Phase 2 / Phase 3CompletedUniversity of Alberta322005-11-012007-11-27

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Short Bowel Syndrome (6)  ·  Bulimia (3)  ·  Obesity (3)  ·  Premature Birth (3)  ·  Binge-Eating Disorder (2)  ·  Cholestasis (2)  ·  Sepsis (2)  ·  Bardet-Biedl Syndrome (1)  ·  Cross Infection (1)  ·  Digestive System Diseases (1)  ·  Emotional Eating (1)  ·  Feeding and Eating Disorders (1)  ·  Infant Nutrition Disorders (1)  ·  Infant, Premature, Diseases (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (27)  ·  Signs and Symptoms (27)  ·  Signs and Symptoms, Digestive (27)  ·  Pathologic Processes (10)  ·  Digestive System Diseases (8)  ·  Gastrointestinal Diseases (6)  ·  Intestinal Diseases (6)  ·  Malabsorption Syndromes (6)  ·  Nutritional and Metabolic Diseases (6)  ·  Postoperative Complications (6)  ·  Nutrition Disorders (5)  ·  Body Weight (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Mental Disorders (3)

Interventions

teduglutide (6)  ·  ALX-0600 (5)  ·  soybean oil, phospholipid emulsion (4)  ·  fish oil triglycerides (2)  ·  setmelanotide (2)  ·  Bupropion (1)  ·  ClinOleic (1)  ·  Fat Emulsions, Intravenous (1)  ·  Fish Oils (1)  ·  Glutamine (1)  ·  Parenteral Nutrition (1)  ·  Rimonabant (1)  ·  Standard of Care (1)  ·  Topiramate (1)  ·  amino-acid, glucose, and electrolyte solution (1)

Sponsors

Shire (6)  ·  Baxter Healthcare Corporation (2)  ·  Fresenius Kabi (2)  ·  HK inno.N Corporation (2)  ·  Rhythm Pharmaceuticals, Inc. (2)  ·  B. Braun Melsungen AG (1)  ·  Emory University (1)  ·  Janssen-Cilag Farmaceutica Ltda. (1)  ·  NICHD Neonatal Research Network (1)  ·  Pediatrix (1)  ·  Radboud University Medical Center (1)  ·  Sanofi (1)  ·  Sino-Swed Pharmaceutical Corporation (1)  ·  Thammasat University (1)  ·  University of Alberta (1)

Countries

United States (14)  ·  Canada (8)  ·  France (8)  ·  Netherlands (8)  ·  United Kingdom (8)  ·  Germany (6)  ·  Denmark (5)  ·  Poland (5)  ·  Belgium (4)  ·  China (4)  ·  Italy (3)  ·  South Korea (3)  ·  Spain (3)  ·  Finland (2)  ·  Israel (2)

Top investigators

David Meeker, MD (2)  ·  Abbot R. Laptook, MD (1)  ·  Avroy A. Fanaroff, MD (1)  ·  Barbara J. Stoll, MD (1)  ·  Brenda B. Poindexter, MD MS (1)  ·  Charles R. Bauer, MD (1)  ·  David K. Stevenson, MD (1)  ·  Edward F. Donovan, MD (1)  ·  Geert Wanten, MD, PhD (1)  ·  Guillermo Umpierrez, MD (1)  ·  Jacques Rigo, MD, PhD (1)

Results publications

PMID 33006765, PMID 21317170, PMID 24134154, PMID 27507402, PMID 12600870, PMID 15121931, PMID 16099790, PMID 16356432, PMID 16615955, PMID 16818526, PMID 17908750, PMID 17915969, PMID 18055678, PMID 18059467, PMID 18288119, PMID 18716628, PMID 19403482, PMID 20061070, PMID 20473991, PMID 20531018, PMID 22136963, PMID 22237883, PMID 22488002, PMID 22982184, PMID 23147209, PMID 23274148, PMID 23333663, PMID 23587733, PMID 23656848, PMID 29174926, PMID 29761915, PMID 31784300, PMID 32341691, PMID 37889619, PMID 39561769

NIH funding

2004 (2), 2008 (1), 2009 (1), K23DK071646 (1), M01RR000070 (1), M01RR000750 (1), M01RR000997 (1), M01RR001032 (1), M01RR006022 (1), M01RR008084 (1), U01HD036790 (1), U10HD021364 (1), U10HD021373 (1), U10HD021385 (1), U10HD021397 (1)